Interferon alpha-2b improves antitumor effect of hapten DNP-modified autologous tumor vaccine for the treatment of advanced melanoma.

Trial Profile

Interferon alpha-2b improves antitumor effect of hapten DNP-modified autologous tumor vaccine for the treatment of advanced melanoma.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 May 2012

At a glance

  • Drugs Interferon alpha-2b (Primary) ; Melanoma vaccine DNP-VACC (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 May 2012 Planned end date 1 Jan 2010 added as reported by Chinese Clinical Trial Register.
    • 20 Dec 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top